Eli Lilly and Company (NYSE:LLY):
Lilly Reaches Settlement Agreement in U.S. Cialis Patent Litigation.
In the market the company is trading up from yesterday’s close of $82.35.
Eli Lilly and Company also declared a dividend that will be paid on Friday September 8th, 2017. The dividend payment will be $0.520 per share for the quarter or $2.08 annualized. This dividend amount will represent a yeild of $2.53. The ex-dividend date will be on Thursday the 11th of May 2017.
Eli Lilly and Company, launched on January 17, 1901, is involved in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Business’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Business’s Elanco division, which develops, manufactures and markets products for both food animals and companion animals. As of December 31, 2016, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries..
The stock is trading at $83.62 barely above the 50 day moving average which is $80.49 and which is a tad above the 200 day moving average of $79.95. The 50 day moving average went up by +4.17% and the 200 day average went up $3.89 or +4.87%.
The company currently has a P/E ratio of 40.54 and market capitalization is 88.56B. As of the last earnings report the EPS was $2.07 and is projected to be $4.12 for the current year with 1,056,300,000 shares currently outstanding. Next quarter’s EPS is forecasted at $1.04 with next year’s EPS anticipated to be $4.36.
A few brokerages have released opinions on LLY. On November 25 the stock rating was downgraded from “Outperform” to “Market Perform” and a price target of $64.00 was set in an announcement from BMO Capital. Equity analyst BMO Capital lowered the price target and downgraded the stock on November 25 changing the price objective from $100.00 to $64.00 and moving the rating from “Outperform” to “Market Perform”.
On November 25 the company was downgraded to “Neutral” from “Overweight” in a report from Atlantic Equities. On September 8 the stock rating was upgraded from “Neutral” to “Overweight” in a statement from JP Morgan.
May 2 investment analysts at Leerink Swann made no change to the stock rating of “Outperform” but raised the price target from $90.00 to $91.00. On May 1 Credit Suisse left the stock rating at “Outperform” and lowered the price expectation to $91.00 from $105.00.Advertisement